Stocktoria
Citius Pharmaceuticals, Inc. CTXR
Citius Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $90,000 | $90,000 | $90,000 | $90,000 | $75,000 | $50,000 | — |
| R&D expense | $9.2M | $11.9M | $14.8M | $17.7M | $12.2M | $8.8M | $8.6M | $6.6M | $2.9M | $2.9M |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M | -$17.7M | -$15.6M | -$13.8M | -$10.0M | -$7.4M |
| Interest expense | — | — | — | — | $10,839 | $15,673 | $16,443 | $15,838 | $850,789 | $8,994 |
| Income tax | $1.1M | $576,000 | $576,000 | $576,000 | $1,233 | $741 | — | — | — | — |
| Net income | — | — | -$32.5M | -$33.6M | -$23.1M | -$17.5M | -$15.6M | -$12.5M | -$10.4M | -$8.3M |
| EPS (diluted) | $-3.38 | $-5.97 | $-5.57 | $-0.23 | $-0.23 | — | — | — | — | — |
| Operating cash flow | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M | -$16.9M | -$12.4M | -$11.3M | -$8.0M | -$5.9M |
| Free cash flow | — | — | — | — | -$24.3M | -$16.9M | — | — | -$8.0M | — |
| Cash & equivalents | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M | $13.9M | $7.9M | $9.2M | $3.2M | $294,351 |
| Inventory | $22.3M | $8.3M | — | — | — | — | — | — | — | — |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M | $43.8M | $36.7M | $31.1M | $24.4M | $22.0M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M | $10.1M | $9.6M | — | — | — |
| Shareholders' equity | $77.5M | $74.1M | $91.4M | $103.4M | $132.8M | $33.7M | $27.2M | $30.6M | $21.9M | $16.8M |
Growth · year-over-year · Revenue CAGR 12.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | +0.0% | +0.0% | +0.0% | +20.0% | +50.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.